This site is intended for healthcare professionals

European Commission approval for Kaftrio in combination with Ivacaftor to treat cystic fibrosis patients 12 years and older with at least one F508del mutation in the CFTR gene.- Vertex

Read time: 1 mins
Last updated:29th Apr 2021
Published:29th Apr 2021
Condition: Cystic Fibrosis-F508del-gene
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest